Historically, patients diagnosed with castration-resistant prostate cancer (CRPC) have had poor survival rates. In recent years there have been significant advances in the treatment of CRPC. In ...
Feasibility of RNA sequencing to detect TMPRSS2:ERG fusions following laser capture microdissection of prostate cancer. This is an ASCO Meeting Abstract from the 2013 Genitourinary Cancers Symposium.
The management of men with metastatic castration-resistant prostate cancer (CRPC) has taken several leaps forward in the past year, with the demonstration of improved overall survival with three novel ...
Androgen deprivation is the mainstay of advanced prostate cancer treatment. Despite initial responses, almost all patients progress to castration-resistant prostate cancer (CRPC). The understanding of ...
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer
Although we now have four therapies that have been shown to extend survival in patients with metastatic castration-resistant prostate cancer (CRPC) (docetaxel, cabazitaxel, sipuleucel-T and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results